Usman Ali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Usman Ali has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Abrar Ahmed
3 shared publications- Aftab Ullah
School of Medicine, Huaqiao University, 269 Chenghua North Road, Quanzhou, 362021, China, hqu.edu.cn
3 shared publications - Azar Abbas
Institute of Medicine, Shenzhen Institute of Advanced Technology, Shenzhen, Guangdong, People’s Republic of China
3 shared publications - Faisal Raza
Institute of Pharmacy (Institute of TCM Health Industrial Technology), Shandong University of Traditional Chinese Medicine, Jinan, 250355 China
3 shared publications Gang Chen
3 shared publications- Hanif Khan
Department of Radiation Oncology, Penn State Cancer Institute, Hershey Medical Center, Hershey, PA 17033, USA
3 shared publications
Latest Publications
- RetractionOpen Access
- 1 June 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1
Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis [Retraction]
Retraction for the article Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis
- 1 June 2026
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 21, 1
RetractionOpen AccessCyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis [Retraction]
Retraction for the article Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis
- 8 November 2022
- Published by Elsevier in Neuroscience Research
- Vol. 188, 75-87
Ginsenoside Rb1, a principal effective ingredient of Panax notoginseng, produces pain antihypersensitivity by spinal microglial dynorphin A expression
- 8 November 2022
- Published by Elsevier in Neuroscience Research
- Vol. 188, 75-87
Ginsenoside Rb1, a principal effective ingredient of Panax notoginseng, produces pain antihypersensitivity by spinal microglial dynorphin A expression
- Open Access
- 12 December 2021
- Published by Aga Khan University Hospital in Anaesthesia, Pain & Intensive Care
- Vol. 25 (6) , 812-815
Ultrasound guided erector spinae plane catheter for thoracotomy: a case report
Major thoracic surgery results in severe postoperative pain. Epidural analgesia is considered the gold standard for pain management after thoracic surgery. However, epidural blocks are contraindicated in certain clinical conditions. Pain management in such patients poses a unique challenge to the anesthesiologists. Erector spinae plane block (ESPB) is a less invasive and relatively new technique, which has shown promising results. This case report describes the use of ESPB as an alternate analgesic technique. A 65-year-old man underwent thoracotomy and left upper lobe resection. Intraoperative and postoperative pain was managed with intermittent boluses of bupivacaine through the erector spinae plane catheter. Effective analgesia was achieved with minimal morphine consumption in postoperative period. Although central neuraxial blocks are considered to be gold standard for major thoracic surgery but where applicable, alternatives can be opted for better patient outcomes. Key words: Analgesia; Erector spinae plane block; Thoracotomy; Pain control; Neuraxial analgesia Citation: Usman A, Khan AW, Ijaz MK. Ultrasound guided erector spinae plane catheter for thoracotomy: a case report. Anaesth. pain intensive care 2021;25(6):812–815; DOI: 10.35975/apic.v25i6.1707 Received: August 16, 2021, Reviewed: October 28, 2021, Accepted: October 31, 2021
- 12 December 2021
- Published by Aga Khan University Hospital in Anaesthesia, Pain & Intensive Care
- Vol. 25 (6) , 812-815
Open AccessUltrasound guided erector spinae plane catheter for thoracotomy: a case report
Major thoracic surgery results in severe postoperative pain. Epidural analgesia is considered the gold standard for pain management after thoracic surgery. However, epidural blocks are contraindicated in certain clinical conditions. Pain management in such patients poses a unique challenge to the anesthesiologists. Erector spinae plane block (ESPB) is a less invasive and relatively new technique, which has shown promising results. This case report describes the use of ESPB as an alternate analgesic technique. A 65-year-old man underwent thoracotomy and left upper lobe resection. Intraoperative and postoperative pain was managed with intermittent boluses of bupivacaine through the erector spinae plane catheter. Effective analgesia was achieved with minimal morphine consumption in postoperative period. Although central neuraxial blocks are considered to be gold standard for major thoracic surgery but where applicable, alternatives can be opted for better patient outcomes. Key words: Analgesia; Erector spinae plane block; Thoracotomy; Pain control; Neuraxial analgesia Citation: Usman A, Khan AW, Ijaz MK. Ultrasound guided erector spinae plane catheter for thoracotomy: a case report. Anaesth. pain intensive care 2021;25(6):812–815; DOI: 10.35975/apic.v25i6.1707 Received: August 16, 2021, Reviewed: October 28, 2021, Accepted: October 31, 2021
- Open Access
- 7 September 2021
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 16, 6203-6204
Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis [Corrigendum]
Corrigendum for the article Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis
- 7 September 2021
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 16, 6203-6204
Open AccessCyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis [Corrigendum]
Corrigendum for the article Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis
- 1 August 2021
- Published by Elsevier in Biochemical Pharmacology
- Vol. 190, 114600
Cynandione A and PHA-543613 inhibit inflammation and stimulate macrophageal IL-10 expression following α7 nAChR activation
- 1 August 2021
- Published by Elsevier in Biochemical Pharmacology
- Vol. 190, 114600
Cynandione A and PHA-543613 inhibit inflammation and stimulate macrophageal IL-10 expression following α7 nAChR activation
- RetractedOpen Access
- 1 July 2021
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 16, 4451-4470
Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis
Background: Liver fibrosis is a chronic liver disease with excessive production of extracellular matrix proteins, leading to cirrhosis, hepatocellular carcinoma, and death. Purpose: This study aimed at the development of a novel derivative of polyethyleneimine (PEI) that can effectively deliver transforming growth factor β (TGFβ) siRNA and inhibit chemokine receptor 4 (CXCR4) for TGFβ silencing and CXCR4 Inhibition, respectively, to treat CCl4-induced liver fibrosis in a mouse model. Methods: Cyclam-modified PEI (PEI-Cyclam) was synthesized by incorporating cyclam moiety into PEI by nucleophilic substitution reaction. Gel electrophoresis confirmed the PEI-Cyclam polyplex formation and stability against RNAase and serum degradation. Transmission electron microscopy and zeta sizer were employed for the morphology, particle size, and zeta potential, respectively. The gene silencing and CXCR4 targeting abilities of PEI-Cyclam polyplex were evaluated by luciferase and CXCR4 redistribution assays, respectively. The histological and immunohistochemical staining determined the anti-fibrotic activity of PEI-Cyclam polyplex. The TGFβ silencing of PEI-Cyclam polyplex was authenticated by Western blotting. Results: The 1H NMR of PEI-Cyclam exhibited successful incorporation of cyclam content onto PEI. The PEI-Cyclam polyplex displayed spherical morphology, positive surface charge, and stability against RNAse and serum degradation. Cyclam modification decreased the cytotoxicity and demonstrated CXCR4 antagonistic and luciferase gene silencing efficiency. PEI-Cyclam/siTGFβ polyplexes decreased inflammation, collagen deposition, apoptosis, and cell proliferation, thus ameliorating liver fibrosis. Also, PEI-Cyclam/siTGFβ polyplex significantly downregulated α-smooth muscle actin, TGFβ, and collagen type III. Conclusion: Our findings validate the feasibility of using PEI-Cyclam as a siRNA delivery vector for simultaneous TGFβ siRNA delivery and CXCR4 inhibition for the combined anti-fibrotic effects in a setting of CCl4-induced liver fibrosis.
- 1 July 2021
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 16, 4451-4470
RetractedOpen AccessCyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis
Background: Liver fibrosis is a chronic liver disease with excessive production of extracellular matrix proteins, leading to cirrhosis, hepatocellular carcinoma, and death. Purpose: This study aimed at the development of a novel derivative of polyethyleneimine (PEI) that can effectively deliver transforming growth factor β (TGFβ) siRNA and inhibit chemokine receptor 4 (CXCR4) for TGFβ silencing and CXCR4 Inhibition, respectively, to treat CCl4-induced liver fibrosis in a mouse model. Methods: Cyclam-modified PEI (PEI-Cyclam) was synthesized by incorporating cyclam moiety into PEI by nucleophilic substitution reaction. Gel electrophoresis confirmed the PEI-Cyclam polyplex formation and stability against RNAase and serum degradation. Transmission electron microscopy and zeta sizer were employed for the morphology, particle size, and zeta potential, respectively. The gene silencing and CXCR4 targeting abilities of PEI-Cyclam polyplex were evaluated by luciferase and CXCR4 redistribution assays, respectively. The histological and immunohistochemical staining determined the anti-fibrotic activity of PEI-Cyclam polyplex. The TGFβ silencing of PEI-Cyclam polyplex was authenticated by Western blotting. Results: The 1H NMR of PEI-Cyclam exhibited successful incorporation of cyclam content onto PEI. The PEI-Cyclam polyplex displayed spherical morphology, positive surface charge, and stability against RNAse and serum degradation. Cyclam modification decreased the cytotoxicity and demonstrated CXCR4 antagonistic and luciferase gene silencing efficiency. PEI-Cyclam/siTGFβ polyplexes decreased inflammation, collagen deposition, apoptosis, and cell proliferation, thus ameliorating liver fibrosis. Also, PEI-Cyclam/siTGFβ polyplex significantly downregulated α-smooth muscle actin, TGFβ, and collagen type III. Conclusion: Our findings validate the feasibility of using PEI-Cyclam as a siRNA delivery vector for simultaneous TGFβ siRNA delivery and CXCR4 inhibition for the combined anti-fibrotic effects in a setting of CCl4-induced liver fibrosis.
- 15 October 2019
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 26 (9) , 643-647
Acupuncture/Electroacupuncture as an Alternative in Current Opioid Crisis
Opioid drugs are the first line of defense in severe pain but the adverse effects associated with opioids are considered as a serious issue worldwide. Acupuncture/electroacupuncture is a type of Chinese medicine therapy which is an effective analgesic therapy, well documented in animals and human studies. Electroacupuncture stimulation could release endogenous opioid peptides causing analgesia in a variety of pain models. It can be used as an alternative therapy to control the opioid crisis.
- 15 October 2019
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 26 (9) , 643-647
Acupuncture/Electroacupuncture as an Alternative in Current Opioid Crisis
Opioid drugs are the first line of defense in severe pain but the adverse effects associated with opioids are considered as a serious issue worldwide. Acupuncture/electroacupuncture is a type of Chinese medicine therapy which is an effective analgesic therapy, well documented in animals and human studies. Electroacupuncture stimulation could release endogenous opioid peptides causing analgesia in a variety of pain models. It can be used as an alternative therapy to control the opioid crisis.